Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 May;51(5):692-6.
doi: 10.1002/mus.24438. Epub 2015 Feb 4.

Oral corticosteroid therapy and present disease status in myasthenia gravis

Tomihiro Imai  1 , Shigeaki Suzuki, Emiko Tsuda, Yuriko Nagane, Hiroyuki Murai, Masayuki Masuda, Shingo Konno, Yasushi Suzuki, Shunya Nakane, Kazuo Fujihara, Norihiro Suzuki, Kimiaki Utsugisawa
Affiliations
Multicenter Study

Oral corticosteroid therapy and present disease status in myasthenia gravis

Tomihiro Imai et al. Muscle Nerve. 2015 May.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Muscle Nerve. 2015 Sep;52(3):470. doi: 10.1002/mus.24754. Epub 2015 Aug 8. Muscle Nerve. 2015. PMID: 26264484 No abstract available.

Abstract

Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG).

Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status.

Results: Achievement of MM or better at peak PSL dose (odds ratio 12.25, P < 0.0001) and combined use of plasma exchange/plasmapheresis (PE/PP) and/or intravenous immunoglobulin (IVIg) (odds ratio 1.92, P = 0.04) were associated positively, and total PSL dose during the past year (odds ratio 0.17, P = 0.03) was associated negatively with present MM or better status.

Conclusions: Higher PSL dose and longer PSL treatment do not ensure better outcome. In the absence of a good response, the PSL dose should be decreased by combining with modalities such as PE/PP or IVIg.

Keywords: cross-sectional study; immunomodulation therapy; myasthenia gravis; postintervention status; prednisolone.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources